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Abstract. The adhesion of polymorphonuclear leuko-
cytes (PMNs) to vascular endothelial cells (EC) is an
early and fundamental event in acute inflammation.
This process requires the regulated expression of mole-
cules on both the EC and PMN . EC stimulated with
histamine or thrombin coexpress two proadhesive mole-
cules within minutes : granule membrane protein 140
(GMP-140), a member of the selectin family, and plate-
let-activating factor (PAF), a biologically active phos-
pholipid. Coexpression of GMP-140 and PAF is required
for maximal PMN adhesion and the two molecules act
in a cooperative fashion . The component of adhesion
mediated by EC-associated PAF requires activation of
CD11/CD18 integrins on the PMN and binding of these
heterodimers to counterreceptors on the EC. GMP-140
also binds to a receptor on the PMN ; however, it
tethers the PMN to the EC without requiring activa-
DHESION of polymorphonuclear leukocytes (PMN)'
to endothelium is an early, requisite event in the
.L Jk acute inflammatory response (Movat, 1985 ; Osborn,
1990). Binding ofPMNs to the endothelium can be rapid and
transient, occurring within minutes under some conditions
(Clark and Clark, 1935 ; Marchesi, 1985 ; Movat, 1985), or
it can develop over hours depending on the factors that incite
inflammation or tissue damage. This variable time course in-
dicates that molecular mechanisms of adhesion are differ-
ently induced or regulated.
PMNs can rapidly alter adhesive molecules on their sur-
faces in response to specific stimuli . The CDI I/CD18 glyco-
proteins (Q2 or leukocyte integrins) are constitutively ex-
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1. Abbreviations used in thispaper: EC, endothelial cells; GMP-140, gran-
ule membrane protein 140; PAF, platelet activating factor; PMN, poly-
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tion of CD1I/CD18 integrins. This component of the
adhesive interaction is blocked by antibodies to GMP-
140 or by GMP-140 in the fluid phase. Experiments
with purified GMP-140 indicate that binding to its
receptor on the PMN does not directly induce PMN
adhesiveness but that it potentiates the CD11/CD18-de-
pendent adhesive response to PAF by a mechanism
that involves events distal to the PAF receptor. Tether-
ing of the PMN to the EC by GMP-140 may also be
required for efficient interaction of PAF with its recep-
tor on the PMN. These observations define a complex
cell recognition system in which tethering of PMNs by
a selectin, GMP-140, facilitates juxtacrine activation of
the leukocytes by a signaling molecule, PAR The lat-
ter event recruits the third component of the adhesive
interaction, the CD11/CD18 integrins.
pressed in the plasma membranes and in subcellular
granules of PMNs (Springer, 1990) . When the PMN is acti-
vated, there is a rapid qualitative alteration in CD11/CD18
heterodimers present on the PMN surface ("functional up-
regulation" or "activation") that makes them competent to
bind to counterreceptors on the endothelial cells (EC)
(Kishimoto et al ., 1990). This mechanism is clearly involved
in PMN adhesion and emigration in vivo (Anderson and
Springer, 1987; Kishimoto et al ., 1990). A second surface
molecule that can be rapidly altered on the plasma mem-
brane, LAM-1 or LEC-CAM-1, may play a role in targeting
PMNs to inflammatory sites (Kishimoto et al., 1989; Wat-
son et al ., 1991). Other proadhesive molecules with altered
expression on activated PMNs have been identified (Singer
et al., 1989 ; Bohnsack et al., 1990), but their roles in PMN
binding in acute inflammation have not been defined.
EC are also activated in inflammatory states and express
molecules on their surfaces that mediate adhesion of PMNs
(Zimmerman et al., 1990a,c; McEver, 1991). We previously
223showed that cultured human EC stimulated with thrombin or
certain other agonists become proadhesive for PMNs within
minutes (Zimmerman et al., 1985 ; McIntyre et al., 1986;
Lewis et al., 1988; Zimmerman and McIntyre, 1988; Zim-
merman et al., 1990a) . Similar events may occur in the en-
dothelium of postcapillary venules in vivo (Clark and Clark,
1935; Grant, 1973) . Rapid EC-dependent PMN adhesion in-
volves the CDII/CD18 integrins; the binding is not com-
pletely blocked by anti-CD18 antibodies, suggesting a
CDl l/CDl8-independent component ofthe adhesive interac-
tion (Zimmerman and McIntyre, 1988) . Some of the PMNs
that bind to thrombin-stimulated EC are activated as evi-
denced by polarization (Zimmerman et al., 1985; McIntyre
et al ., 1986) and other criteria (our unpublished observa-
tions) . Thus, molecules expressed by the activated EC medi-
ate functional alterations in the PMNs as well as adhesion
to the EC plasma membrane. In rapidly activated EC,
platelet-activating factor (PAF), a biologically active phos-
pholipid, is transiently synthesized and transported to the
plasma membranes where it mediates PMN adhesion by
ligating a receptor on the PMN (Zimmerman et al., 1990a).
Since PAF is not released into the fluid phase under these
conditions (Prescott et al., 1984 ; McIntyre et al ., 1985),
these experiments demonstrated an unusual mechanism of
intercellular interaction involving the regulated surface ex-
pression of a phospholipid rather than a protein. However,
our observations also suggested that adhesion is influenced
by a second molecule that is expressed by EC with kinetics
similar to PAF accumulation (Zimmerman et al ., 1985).
Granule membrane protein-140 (GMP-140) is the second
proadhesive molecule.
GMP-140 (PADGEM, CD62)is a membrane glycoprotein
constitutively present in secretory granules of platelets and
EC. It is translocated within minutes to the plasma mem-
branes following cellular activation (Stenberg et al., 1985;
Berman et al ., 1986; Hattori et al ., 1989; Bonfanti et al.,
1989; McEver et al., 1989) . After surface expression on
histamine-activated EC, GMP-140 is rapidly reinternalized
(Hattori et al., 1989) . GMP-140 has a predicted structure
(Johnston et al., 1989) that is similar to that of ELAM-1
(Bevilacqua et al ., 1989)and LAM-1 (Camerini et al ., 1989;
Lasky et al., 1989; Siegelman et al ., 1989; Tedder et al .,
1989) both of which are involved in EC-leukocyte interac-
tions under other circumstances. These three related pro-
teins have been termed selectins. Human neutrophils and
other myeloid cells bind to purified, immobilized GMP-140,
to cells transfected with GMP-140 cDNA, and to activated
platelets and EC that express GMP-140 on their surfaces
(Larsen et al., 1989; Geng et al., 1990; Hamburger and
McEver, 1990) .
The relative roles ofPAF and GMP-140 in rapid EC-PMN
interactions are unclear. It is also unknown ifGMP-140 mod-
ifies the CDl I/CD18 adhesive mechanism or other activation
responses of neutrophils when expressed by activated EC.
This issue is particularly important because others have re-
ported that GMP-140 inhibits CD11/CD18-mediated adhe-
siveness of PMNs under some conditions (Gamble et al .,
1990). Here we show that GMP-140 and PAF are coexpressed
on rapidly activated EC and define the contributions of each
to the binding and activation of PMNs. Unexpectedly, we
found that they act cooperatively rather than in an additive
fashion, and evidence that GMP-140, while not directly ac-
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tivating CDl l/CD18 integrins on the PMN, facilitates the re-
cruitment of this component of the adhesion mechanism
by PAF.
Materials andMethods
Reagents
Histamine was from Sigma Chemical Co. (St. Louis, MO). PAF was pur-
chased from Avanti Polar Lipids, Inc. (Birmingham, AL). Purified human
thrombin was a gift from John Fenton (Albany, NY). Recombinant human
TNFce was provided by Genentech, Inc. (South San Francisco, CA) and
recombinant human ILIce was provided by Peter Lomedico (Dept. of Mo-
lecular Genetics, Hoffman-La Roche Inc., Nutley, NJ). "'In oxine was
purchased from the Radiopharmacy Service at the University of Utah, and
human serum albumin (25 % USP) from Miles Inc. (Elkhart, IN). Medium
199 and HBSS were from Whittaker Bioproducts (Walkersville, MD).
Endothelial Cells
Monolayers of human umbilical vein EC were cultured in multiwell plates
(16- or 24-mmwells; Costar, Inc. Cambridge, MD)as described (Zimmer-
manet al., 1990b) . Tightly confluent, primary monolayers were used for
these experiments.
MeasurementofNeutrophil Binding to EC
and toProtein Matrices
Human blood was obtained from volunteers after informed consent. Neu-
trophils were isolated and labeled with 1"Indium as described (Zimmerman
et al ., 1985). The binding assays have been reported previously (Zimmer-
man et al., 1985; Zimmerman and McIntyre, 1988). Briefly, EC mono-
layers were washed with HBSS and incubated with control buffer or an
agonist in HBSS with 0.5 % human serum albumin (HBSS/A) for variable
time periods. In some experiments antibodies were added to the incubation
mixtures as described in detail below. Theincubation mixture was then re-
moved, the monolayers were rapidly washed with HBSS, and "'In-labeled
PMNs were added and incubated for 5 min. In certain experiments, includ-
ing those with EC treated with antibodies against GMP-140, the wash step
was omitted (see below). In additional experiments, PMNs were pretreated
with antibodies or with PAFreceptor antagonists as described in detail be-
low. After the incubation period nonadherent PMNs were removed, the
monolayers were washed with HBSS, the adherent radiolabeled PMNs and
the EC were solubilized, and the fraction ofadherent PMNs (percent ofto-
tal radiolabeled PMNs added) was quantitated. In incubations with TNFa
or IL-1, the cytokine or control buffer was added to EC in complete culture
medium for 3.5 or 4 h . The medium was then removed, the EC were
washed, and "'In-labeled PMNadhesion was determined after a 5-min in-
cubation. In some experiments EC were washed, "'In-labeled PMNs were
added followed by addition of control buffer or anagonist (PAF or fMLP),
and PMN binding was measured after 5,min.
"'In-labeled PMNbinding to protein matrices, made by treating culture
wells with gelatin (2,0001Lg/ml; type A; Fisher Scientific Co., Fair Lawn,
NJ) for 1 h at 37°C, was measured as previously described (Lewis et al .,
1988; Bohnsack et al., 1990). Briefly, the matrices were washed once with
HBSS (37°C), "'In-labeled PMNs were layered over them, PAF or an-
other agonist wasadded, andadhesion was measured after a5- or 15-min
incubation period.
Experiments withAntibodies to GMR140
The preparation of rabbit polyclonal antisera (Stenberg et al., 1985) and
monoclonal IgG's (Geng et al., 1990) against GMP-140has been described
previously. Apolyclonal anti-GMP140 was prepared by immunizing agoat
with 1 mg of purified human platelet GMP-140 in complete Freund's ad-
juvant. Theanimal wasboosted 1 mo later with 20014g of GMP140 in in-
complete Freund's adjuvant. IgGwaspurified from serum by sequential 30
and50% ammonium sulfate precipitations and gel filtration on a G200 col-
umn equilibrated in 0.1 M NaCl, 1 mM MOPS, and 0.02% sodium azide.
Thepooled IgGwas monospecific for GMP140 as assayed by Western blot-
ting of human platelet lysates, reacting only with a band that co-migrated
with purified human GMP140. Thegoat IgGand mAbs were diluted to a
concentration of 1 mg/ml in HBSS/A and frozen in aliquots until they were
used.
224In experiments to determine the effect of antibodies on PMN adhesion
toactivated EC, the EC monolayers were washed, HBSS/A was added, anti-
body against GMP-140 or control antibody was added, an agonist (hista-
mine, thrombin) or control buffer was added, and the monolayers were in-
cubated for the specified period oftime in an atmosphere of5% C02, 95 %
air at 37°C. The incubation solutions were removed and "'In-labeled
PMNs were added and incubated for 5 min at 37°C, 5% C02 without agi-
tation. There was no wash step between incubation of the EC and addition
of the PMNs, as there was in certain other experiments. In most experi-
ments the PMN solutioncontained anti-GMP-140 or control antibody in the
same concentration as did the solutions incubated with EC because maxi-
mal inhibition required that the antibody was present during incubation of
the PMNs with the EC (an unpublished observation). Antibody was added
to the PMN solutions and they were gently mixed at room temperature im-
mediately before addition to the EC. Control antibodies were included in
each experiment. Monoclonal IgG's S12, T10, and Tab were studied in ex-
periments with monoclonal anti-GMP-140 antibodies. mAb S12 does not
inhibit PMN binding to purified GMP140 or to histamine-activated EC
(Geng et al., 1990), even though it identifies an epitope on GMP-140
(McEver and Martin, 1984). In this series ofexperiments S12 also did not
block PMN adhesionto EC activated with thrombin (not shown). mAb T10,
directed against the platelet IIb/IIa complex (McEver et al., 1983), Tab, di-
rected against platelet glycoprotein Ilb (McEver et al., 1983), and nonim-
mune murine IgG did not block adhesion to histamine- or thrombin-stimu-
lated EC. In experiments with polyclonal rabbit antisera or monospecific
goat IgGagainst GMP-140, nonimmune sera and polyclonalantisera orpuri-
fied IgG against von Willebrand factor, vitronectin, fibronectin, comple-
ment factors (C3, C3a), or platelet glycoproteins IIb or IIIa were studied
inparallel; these reagents reduced PMN adhesionby 20% orless. The prep-
aration of rabbit antisera against glycoprotein IIb/IIIa was previously de-
scribed (Bray et al., 1986). Charles J. Parker generously provided rabbit
antiseraagainstvitronectin (Parker et al., 1988). Nonimmune rabbit serum
and rabbit polyclonal anti-vWF were from Behring Diagnostics (La Jolla,
CA) or Dako Corp. (Santa Barbara, CA), rabbit antiserum against C3a was
from Behring Diagnostics. Mouse and goat nonimmune IgG, goat poly-
clonal anti-human fibronectin IgG, and goatpolyclonal anti-human C3 were
from Cappel (Cooper Biomedical Corp., Westchester, PA).
Experiments with FluidphaseGMR140
GMP-140 was purified from human platelets as described (Johnston et al.,
1989b; Moore et al ., 1990). It was stored as a stocksolution in0.1 M NaCI,
20 mM Tris and 0.01% (vol/vol) Lubrol® under sterile conditions at 4°C. In
experiments to determine its effect on PMN adhesion to activated EC, the
GMPI40 or control buffer was added to PMN solutions in various concen-
trations followed by incubation at room temperature with gentle mixing for
20 min. The PMN suspensions were then added to EC monolayers and ad-
hesion was determined. Fluid-phase GMP140 was continuously present
during incubation of PMNs with the EC. Fibrinogen (Sigma Chemical Co.)
and/or equivalent concentrations of Lubrol (vol/vol), the detergent used to
solubilize the GMP-140, were used as controls in each experiment.
In experiments to determine theeffectofGMP-140 on unstimulated PMN
adhesion to resting unactivated EC (Fig. 6) or the response of GMP-
140-treated PMNs to exogenous PAF or other agonists (Figs. 7-10), PMNs
were treated with GMP140, fibrinogen, or Lubrol as described above and
then added to EC monolayers. In some experiments (Figs. 6-9) the PMNs
were centrifuged at 450 g for 5 min at room temperature and resuspended
in fresh HBSS/A before adding them to the EC. Adhesion was determined
after a 5-min incubation period. In experiments in which the PMN were
stimulated with PAF, fMLP, or PMA, the agonist was added in the fluid
phase at the beginning of the 5-min incubation period with the EC.
Assays ofGMP-140 Expression on thePlasma
Membranes ofActivated EC
Measurement of the binding ofmAb S12 (McEver and Martin, 1984) to the
surface ofhistamine-activated EC was doneby a modification ofthe method
of Hattori et al. (1989). EC were incubated with histamine (10-4 M) in
HBSS/A for various times. The incubation solution was removed and the
monolayers were fixed with 1% formaldehyde as described (Hattori et al.,
1989) . They were washed three times with buffer and incubated with buffer
containing mAb S12, mAb TIO, or nonimmune murine IgG for 45 min at
room temperature. Each IgGwas present in a final concentration of2 pg/ml.
The antibody solutions were removed and the EC monolayers were washed
three times. A radiolabeled sheep anti-mouse IgG (Amersham, Arlington
Heights, IL) (1:100 dilution) was then added and incubated for 20 min at
Lorant et al. Activated EC Bind PMNvia GMP-140and PAF
room temperature. The monolayers were washed three times with buffer,
solubilized with 1 N NH40H, and the radioactivity was counted in a
gamma counter. In parallel incubations EC were treated with control buffer
in place of histamine and binding of S12, T10, or IgG was measured.
Experimentswith Competitive PAF
Receptor Antagonists
PMNs were pretreated with control buffer or L659,989 (100 pM) for 5 min
at roomtemperature before additionto EC monolayers. The specificity and
efficacy of the competitive antagonist were assessed in the following way:
In four experiments pretreatment of PMNs with L659,989 inhibited PMN
binding to histamine-activated EC by 52% (range 32-77%). L659,989 in-
hibited PAF-stimulated (10-1 M) binding to quiescent EC (i.e., no hista-
mine stimulation) by 76% (7577% inhibition) but had no effect on fMLP-
stimulated (10-7 M) adhesion in parallel incubations (0% inhibition).
These results are similar to those using L659,989 and its analogs to block
PMN adhesion to thrombin-activated EC (Zimmerman et al., 1990a). The
conditions required for preparation of solutions of the antagonist and the
appropriate control buffer, and additional experiments documenting its
efficacy and specificity, were described previously (Zimmerman et al.,
1990a). L659,989 was generously provided by John Chabala (Merck Re-
search Laboratories, Rahway, NJ).
Experimentswith CDII1CD18-deficientPMNs
andAntibodies against CD111CD18
Neutrophils from a subject with complete absence of surface expression of
CDII/CD18 glycoproteins in both the resting and stimulated state (leuko-
cyte adhesion deficiency) (Bohnsack et al., 1990), were isolated and radio-
labeled using the same method as with neutrophils from control subjects.
Binding assays were done as with control neutrophils, which were studied
in parallel. The anti-CD18 mAbs IB4 (IgG 2a, Wright et al., 1983; a gift
from Samuel Wright, Rockefeller University, New York) and 60.3 (IgG 2a;
Beatty et al., 1983; agift from Patrick Beatty, University of Utah) were di-
luted to a concentration of 1 mg/ml in PBS or HBSS and added to PMN
suspensions in a final concentration of 10 ug/ml for each antibody. The
PMNs were preincubated with the antibodies, or with control antibodies,
for 10 min at room temperaturebefore addition to EC monolayers. The con-
trol antibodies were mAb 60.5 (Gamble et al., 1985) or W6/32 (American
Type Culture Collection, Rockville, MD) which are both IgG 2a immuno-
globulins directed against HLA class I molecules. mAb 60.1 (supplied by
Patrick Beatty), an anti-CD11b IgGI (Beatty et al., 1983; Harlan et al.,
1985), was stored in HBSS/A in a concentration of4 mg/ml and was added
to PMN suspensions in a final concentration of 40,ug/ml. Preincubations
were done as with mAbs 60.3 and 1B4; nonimmune polyclonal murine IgG
in the same concentration was the control.
Inhibition ofPMNActivation Responses
PMNs were isolated and labeled with IIIIndium. They were then centri-
fuged at 1,350RPM for5 min atroomtemperature. The bufferwas decanted
and the pellet was resuspended in 10 ml of ice-cold 2.5% glutaraldehyde
and incubated at 4°C for 5 min. The PMNs were centrifuged (1,350 RPM,
5 min at room temperature), resuspended in HBSS with 0.5% albumin
(room temperature), and used in the adhesion assay. Control PMNs were
treated in the same way but were incubated in buffer rather than glutaralde-
hyde. Fixed or control PMNs were added to EC monolayers that had been
preincubated with buffer, thrombin, orhistamine as described above. Adhe-
sion of the PMNs was determined after a 5-min incubation. In additional
experiments PMNs were fixed with paraformaldehyde as described (Bevil-
acqua et al., 1985), chilled to 4°C as described in the legend to Fig. 2, or
treated with the metabolic inhibitors 2-deoxyglycose and sodium azide as
described (Marlin and Springer, 1987). Control neutrophils were tree ed
with appropriate solvents, etc., in parallel.
Results
GMP-140andPAFActCooperatively
andBothAreRequiredforMaximalPMNAdhesion
to Thrombin- orHistamine-activated EC
We have shown that thrombin (Zimmerman et al ., 1985) and
histamine (Geng et al., 1990) stimulate EC to become adhe-
225Figure 1. PAF and GMP-140 are required for maximal PMN bind-
ing to thrombin-activated EC. EC monolayers were washed with
buffer and incubated with control buffer or thrombin (2 U/ml) in
HBSS/A for 10 min . In some wellsmAb Gl (10 ug/ml) was added
immediately before the agonist . After the 10-min incubation, the
solutions were removed and "'In PMNs that had been pretreated
with control buffer, or the competitive PAF receptor antagonist
L659,989 (100 AM), were added . In monolayers treated with mAb
Gl, the antibody (10 hg/ml) was also present in the PMN suspen-
sions. After a 5-min incubation PMN adhesion was determined .
The percent inhibition resulting from blocking the PAF receptor on
the PMNs or GMP-140 on the EC is shown in brackets . Both re-
agents (L659, 989, andmAb GI) added together in the same incuba-
tion resulted in 100% inhibition (not shown) .
sive for neutrophils, and that under these conditions EC ex-
press two molecules, PAF and GMP-140, that could explain
the increased adhesiveness . These responses occur within
minutes, so we first determined the kinetics of the three
events to see whether they were coincident or could be sep-
arated . We found that histamine stimulated the adhesion of
neutrophils, expression ofGMP-140 on the EC surface, and
accumulation ofPAF all with a peak between 5 and 10 min .
Thus, the time of appearance ofGMP-140 on the EC surface
and the synthesis ofPAF were compatible with their partici-
pation in the adhesion event . Polyclonal and monoclonal an-
tibodies that block the adhesive properties of GMP-140 in
purified systems also inhibited PMN adhesion to histamine-
activatedEC at the peak ofthe adhesive interaction, whereas
control antibodies did not (Geng et al ., 1990 ; and data not
shown) . The mean inhibition was 65-85% depending on the
antibody. Anti-GMP-140 antibodies also inhibited PMN ad-
hesion to EC activated with thrombin for 5-10 min (not
shown) . The inhibition was equally potent and specific as
with histamine-activatedEC. However, blocking the PAF re-
ceptor on the PMN potently inhibits PMN adhesion at this
time point (Zimmerman et al ., 1990a), indicating that RAF
also mediates adhesion .
To examine the relative contributions of GMP-140 and
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PAF in the adhesive interaction, we blocked thePAF recep-
tor on PMNs, GMP-140 on activated EC, or both in parallel
incubations using a competitive antagonist of thePAF recep-
tor and a blocking mAb to GMP-140 . Under the conditions
of these experiments, the mAb against GMP-140, G1, does
not inhibit PAF-stimulated PMN adhesiveness, and the PAF
receptor antagonist, L659,989, does not inhibit PMN adhe-
sion to EC expressing GMP-140 but not PAF (Patel et al .,
1991 ; and data not shown) . In an experiment with thrombin-
activated EC, each reagent, used alone, inhibited PMN adhe-
sion by >50%, demonstrating that the components of adhe-
sion mediated by GMP-140 andPAF are cooperative and not
simply additive (Fig . 1) . The pattern of inhibition also indi-
cated a cooperative mechanism in histamine-activated EC
('table 1) . When the PAF receptor antagonist and mAb GI
were added together (Table I), PMN binding was blocked
completely. Thus, PAF and GMP-140 appear to completely
account for the EC-dependent PMN adhesion under these
conditions .
The Effect ofPAFIs to Upregulate
CDIIICD18 Integrins on thePMNs; GMP-140 Tethers
the Leukocyte Independently ofCDII1CD18
The requirement for both PAF and GMP-140 for maximal
adhesion and the apparent cooperative nature ofthe adhesion
suggested that the molecular events involved are complex .
Therefore, we examined the mechanism(s) by which each of
these molecules contributes to the binding ofPMNs to acti-
vated EC. The PAF receptor is linked to effector systems that
require activation of the leukocyte (Prescott et al ., 1990 ;
Zimmerman et al ., 1990c) . We asked whether the adhesion
of PMN to EC stimulated with histamine or thrombin re-
quired that the PMN be metabolically intact . PMNs were
fixed with paraformaldehyde or glutaraldehyde, treated with
metabolic inhibitors, or cooled to 4 °C . In control experi-
ments each of these manipulations blocked PMN adhesion
in response to exogenous PAF in solution (not shown) . Each
of them also dramatically reduced, or completely blocked,
the adhesion of PMN to thrombin- or histamine-activated
EC (Fig . 2) . In contrast, neither fixing nor cooling inhibits
the binding ofPMNs to GMP-140 (Geng et al ., 1990 ; Moore
et al ., 1991) .
The adhesive responseofPMNs toPAF in solution depends
on functional upregulation of CDII/CD18. In multiple ex-
periments in which PMN adhesion was induced by exoge-
nous PAF in solution, PAF incorporated into liposomes, or
PAF associated with the plasma membranes of unactivated
EC, neutrophil adhesion was blocked by antagonists of the
PAF receptor or antibodies toCD18 (data not shown) . In ad-
Table I. Coexpression ofPAFandGMP-140
MediatesPMNAdhesion to Histamine-stimulatedEC
EC agonist
Histamine
PMN adhesion was measured in "side-by-side" incubations that were done as
those described in the legend to Fig . 1 . The mean results andranges from three
experiments are shown . The data are presented as the percent inhibition of
PMN adhesion compared to controls containing no inhibitor.
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Inhibitor Mean percent inhibition
L659,989 58% (range 32-77%)
G l 80% (range 68-87%)
L659,989 + G1 98% (range 95-100%)Figure 2 . Neutrophil activa-
tion is required for maximal
adhesion to thrombin- or his-
tamine-activated EC. (Left)
ChillingPMNs to 4°C inhibits
adhesion . EC were pretreated
with thrombin or buffer at
37° C for 10 min . Radiolabeled
PMNs were equilibrated at
24°or4°C for 10 minand then
incubated with EC atthesame
temperature for 5 min . The
error brackets indicate the
range of duplicate measure-
ments; bars without brackets
indicate single measurements .
In two additional experiments
(not shown) cooling PMNs to
4°C inhibited their enhanced
adhesion to thrombin-activated
EC (enhanced adhesion reduced by 80% or greater compared to PMNs equilibrated at 37°C) . (Right) Fixation ofPMNs reduces their adhe-
sion to rapidly activated EC. PMNs fixed with glutaraldehyde or control PMNs were added to EC that had been preincubated with buffer
or histamine for 10 min . Adhesion was determined after a5-min incubation . In additional experimentsPMNs were fixed with paraformalde-
hyde, which also inhibited their adhesion to histamine- or thrombin-activated EC (not shown) . Fixed PMN did not adhere to resting EC
in response to PAF or fMLP but adhered to EC induced to express ELAM-1 by treatment with IL-1 or TNFct for 4 h (not shown) .
dition,PMNs from asubjectwithCDll/CDI8 deficiency did
notadhere in response to PAR These integrins also are up-
regulatedby the PAFsynthesized by EC in response to hista-
mine . In three experiments PMNs were pretreated with a
mAb (1114) to CDI8 or control murine IgG and their adhe-
sion to histamine-activated EC was measured . ThemAb to
CDI8 decreasedbindingby a mean of52% . Anti-CDI8mAb
also partially inhibitPMN adhesion to thrombin-stimulated
EC (Zimmerman and McIntyre, 1988) . Thus the adhesion
ofPMNto endotheliumin response to PAF, whetherthePAF
is synthesized and expressed by EC or is pretreated in other
ways, requires activation of CDII/CD18 integrins .
The lack of complete inhibition of PMN adhesion to
thrombin- or histamine-activated EC by antibodies to CDI8
s
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Figure 3 . (Left) CDII/CD18-
deficientPMNs adhereto rap-
idly activatedEC . PMNs from
a control subject or a patient
with CDII/CD18 deficiency
were added to EC that had
been treated with control buff-
er, thrombin (2 U/ml), or his-
tamine (101 M) for 5 min,
and adhesion was determined
aftera 5-min incubation. The
bars indicate single or the
mean of duplicate points in
oneexperiment . In three addi-
tional incubations the adhe-
sion of CDII/CDI8-deficient
PMNs to histamine-stimulated
EC was 2.5-fold greater than adhesion to control EC, andadhesion to thrombin-stimulated EC was twofold greater than control . (Right)
GMP-140 expressed by activated EC mediates CD1l/CDI8-independent PMNbinding . EC were washed and incubated with control buffer
or histamine (10-° M) for5 min . In some wells, mAbs GI, TIO, S12, or nonimmune murine IgG (10 )g/ml for each) were added immedi-
ately before the addition of the agonist . The incubation mixtures were removed and "'In-labeled PMNs from the CDII/CDI8-deficient
subject were added and incubated for5 min followed by determination of the fraction of adherent PMNs . In points treated with immuno-
globulins, the mAb or control IgG was included in the PMN suspension .
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indicated that there is a CDII/CDI8-independent compo-
nent . To confirm this, we studied PMNs from a CDll/CDl8-
deficient subject . The adhesion ofthesePMNs to histamine-
or thrombin-activated EC was increasedby two- to threefold
over that to unstimulated EC (Fig . 3), although the incre-
ment in adhesion was significantly less than that observed
with normal PMNs . These experiments document that there
is an alternative binding mechanism. To test whether this
component is due to GMP-140 we incubated CDII/CD18-
deficient PMNs with rapidly activated EC and examined the
ability of mAb Gl to block the binding . This antibody re-
duced the adhesion to background levels (Fig. 3, right) . We
conclude that GMP-140 can tether thePMN to theEC by a
mechanism that does not require activation of CDII/CD18
O Buffer
9 Histamine MEX
ENEX
I NEX
IgG T10 S12 G1integrins . CDll/CD18-deficient PMNs specifically adhered
to purified, immobilized GMP-140 at both 4° and 37°C (not
shown), consistent with this interpretation .
The binding of GMP140 to its receptor is Call depen-
dent (Geng et al ., 1990), and the CDll/CD18 adhesive
mechanism is dependent on Mgz+ (Kishimoto et al., 1990) .
We found that maximal adhesion to thrombin-activated EC
required both Cal+ and Mgz+ (not shown) . Thus, the diva-
lent cation requirement for PMN adhesion to rapidly acti-
vated EC is consistent with a contribution from both GMP-
140 and PAR
BindingofGMFL140 to PMNs Inhibits TheirAdhesion
to ActivatedEC but not to RestingEC
GMP140 binds to a sialic acid-containing glycoprotein on
PMNs (Moore et al., 1991) . It is unknown if this receptor
is linked to signal transducing systems and if occupancy of
the receptor activates the leukocyte . Therefore it is possible
that, while GMP-140 does not require the CDll/CD18-de-
pendent mechanism (Fig . 3, right), it activates CDll/CD18
integrins (Fig . 3, left) . To examine this issue, we added puri-
fied GMP-140 in solution to PMNs and looked for CDll/
CD18-dependent adhesion to resting, unactivated EC . In
concentrations sufficient to saturate its binding sites on
PMNs, 1-5 pg/ml (Moore et al ., 1991), GMP-140 did not di-
rectly induce adhesiveness ofPMNs (Fig . 4) . In each experi-
ment control incubations demonstrated that the leukocytes
adhered via the CDll/CD18 mechanismwhen stimulated by
fMLP or PAR
In contrast to its lack ofeffect on PMN adhesion to resting
EC, fluid phase GMP-140 inhibited PMN binding to hista-
mine- or thrombin-treated EC. The inhibition was concen-
tration-dependent, with maximal effect at 1-5 /.4g/mlGMP140
(7-35 nM) . The mean inhibition was 74% in four experi-
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Figure 4. Fluid phase GMP140
does not stimulate CDII/CD18-
dependent adhesion to resting
EC . PMNs were added to washed
EC monolayers ; buffer, GMP-
140, orfMLP was added and ad-
hesion was determined after a
5-min incubation period . Some of
the PMNs were pretreated with
the anti-CD18 mAb IB4 (10 Ag/
ml) or with the control mAb W6/
32 (10 FAg/ml) for 10 min at room
temperature before addition to the
EC . A 5-min incubation ofPMNs
withEC was used because of the
transient nature of CDII/CD18-
dependent binding of PMNs to
EC (Zimmerman et al ., 1985 ; Lo
et al ., 1989 ; Carveth et al ., 1989) .
The bars indicate the mean and
range of duplicate points in one
of two experiments with similar
results .
ments with histamine-treated EC and was the same in five
experiments with thrombin-activated EC . Neither a control
protein, fibrinogen, nor the Lubrol present in the purified
GMP-140 reproduced the inhibition ofPMN adhesion (Fig .
5) . The effect of fluid phase GMP140 was specific in these
experiments ; it did not inhibit PMN adhesion toEC induced
to express SLAM-1 by cytokine treatment (not shown) .
GMP-140Pbtentiates Neutrophil Adhesiveness Induced
byPAFand OtherAgonists
The data in Fig. 5 are consistentwith the conclusion that fluid
phaseGMP-140 inhibitedtheadhesionofPMNsto histamine-
activated EC by competing for its binding site on thePMNs .
However, other workers have suggested that soluble GMP-
140 inhibits CDll/CD18-dependent adhesiveness of stimu-
lated PMNs (Gamble et al., 1990) . Therefore we examined
the effect of GMP-140 on PMN adhesion known to depend
on CDll/CD18. We found that GMP140 in the fluid phase
enhanced the adhesion ofPMNs to unactivated endothelium
when they were stimulated with exogenousPAF (Fig . 6) . The
qualitative effect was consistent in multiple experiments done
under a variety of conditions although the magnitude of the
enhancement varied from experiment to experiment (see
Figs . 6-9) . The potentiation of adhesion was maximal at 1-5
gg/ml GMP-140 and was measurable when the PMNs were
treated with GMP-140 for 2, 5, or 20 min (not shown) . The
enhancement occurred when theGMP-140 was continuously
present (not shown) orwhen thePMNs were centrifuged and
resuspended in fresh buffer after pretreatment with GMP-
140 (see Figs . 6-9) . PolymyxinB did notinhibit the potentia-
tion, excluding the possibility that the effect was because of
contaminating endotoxin (not shown) . A control protein,
fibrinogen, in the same concentrations and in the same sol-
vent, did not reproduce the enhancement (see Figs . 6 and 9) .0
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Figure 6. Fluid phase GMP140 enhances PAF-stimulated adhesion
to EC. PMNs were pretreatedwith GMP140 (2 Lglml), fibrinogen
(2 14g/ml), or control buffer for 20 min at room temperature. The
fibrinogen- and buffer-treated PMN suspensions also contained the
same concentration of detergent (Lubrol; see Materials and
Methods) as the GMP140-treated PMNs. After the pretreatment
period the PMNs were sedimented at 450 g for 5 min at room tem-
perature, resuspended in fresh HBSS/A, and added to EC mono-
layers. Control buffer or PAF in the concentrations shown was
added and adhesion to the monolayer was determined after a 5-min
incubation.
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Figure 5. Fluid phase GMP-140
inhibits PMN adhesion to hista-
mine-activated EC. PMNs were
pretreated with GMP-140 solubi-
lized from platelet membranes,
with fibrinogen, or with Lubrol in
the concentrations indicated for
20 min at room temperature with
gentle mixing. They were then
added to EC that had been pre-
treated with histamine (10-° M)
for 5 min. The concentrations of
Lubrol (vol/vol) were equal to
those in the PMN suspensions
containing GMP-140. The figure
indicates single points from one
experiment.
The potentiating effect was blocked by mAb G1, indicating
that the effect is specific, and that binding of GMP140 to the
neutrophil is necessary (Fig. 7). The adhesive response of
GMP140-treated PMNs to PAF was completelyinhibited by
a PAF receptor antagonist (Fig. 8), or by a mAb to CD18
(Fig. 8) . These experiments indicate that ligation of PAF to
its receptor on the PMNs and activation of CDII/CD18 in-
tegrins is required, and that the potentiating effect of GMP
140 is not due to recruitment of an alternative adhesive
mechanism. The results shown in Figs. 7 and 8 demonstrate
that mAb GI blocks only the component of enhanced adhe-
sion mediated by GMP140, whereas blocking the PAF re-
ceptor or the CDl l/CDI8 integrins reduced the adhesion of
PAF-stimulated PMN to, or below, that of PMNs treated
with control buffer.
Certain lectins enhance the response of platelets to PAF
by an apparently selective effect on the PAF receptor (Hwang
and Wang, 1991). Since GMP140 is a lectin, we asked wheth-
er its enhancement of neutrophil adhesion in response to
PAF was specific or whether it also occurred with other agon-
ists. Fluid phase GMP-140 enhanced PMN adhesion in re-
sponse to fMLP, which acts through a different receptor, and
to PMA, which directly activates protein kinase C (Fig. 9).
In two additional experiments we examined the response of
PMN to opsonized zymosan, which uses CDllb/CD18 as a
receptor (Kishimoto et al., 1990) . PMN were incubated in
tissue culture wells that had been coated with GMP-140, al-
bumin, or fibrinogen and then were stimulated with opso-
nized zymosan. PMN adherent to GMP140 generated more
superoxide anion than PMN incubated on the control sur-
faces (not shown) . Thus, the increased PMN responsiveness
in the presence ofGMP-140 was not specific for PAF, but was
observed with agonists that act via different receptors.U W
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The adhesion of PMNs to EC activated with histamine or
thrombin requires three pairs of molecular interactions :
binding of GMP140 to its receptor on the PMN ; binding of
PAF to its receptor on the leukocyte; and binding of
CDll/CD18 glycoproteins to counterreceptors on the EC
(Fig. 10) . The adhesive mechanism involves a novel example
of juxtacrine cell-cell interaction (Massagud, 1990) in
which cell-associated PAF acts as a signal that activates the
PMN Pretreatment --a- Buffer
￿
Buffer
0 Buffer-Pretreated PMNs
GMP-140-Pretreated PMNs
G1 S12
PAF (10'7M)
T10
Figure 8. Enhanced adhesion of
GMP140-pretreated PMN in re-
sponse to PAF requires the PAF
receptor and CDII/CD18 inte-
grins. PMN were pretreated with
control buffer or GMP140 (2 p,g/
ml) for 10 minasdescribedin Fig.
6. They were then pelleted, resus-
pended in fresh HBSS/A, and in-
cubated with a PAF receptor an-
tagonist (L659,989, 100 /g/ml),
an anti-CD18, mAb, (IB4, 10 pg/
ml), a control mAb (W6/32, 10
14g/ml) or control buffer for an ad-
ditional 10 min. Following this,
they were added to EC monolay-
ers, bufferor PAF was added, and
adhesion was determined after a
5-min incubation. In a parallel set
of points, PMN were pretreated
with fibrinogen (2 tcg/ml) and the
PAF receptor antagonist, antibod
ies, or control solutions. Fibrinogen did not enhance PAF-stimulated adhesion, and the adhesion of PMNs pretreated with fibrinogen and
stimulated with PAF was blocked by L659,989 and by IB4 but not by W6/32. The data are not shown to simplify the figure.
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PMN, recruiting participation of adhesion effectors, the
CDll/CD18 integrins. Their binding amplifies the avidity of
the tethering effect of GMP-140. The GMP140 component,
while relatively weak by itself under these conditions, is es-
sential for effective operation ofthe PAF component and may
facilitate PAF-stimulated CDll/CD18 activation.
The intercellular interaction begins with unactivated EC
and unactivated PMNs. Histamine or thrombin, acting
through EC surface receptors, induce translocation of GMP-
140 from secretory granules to the plasma membrane where
Control mAb
￿
Anti-CD18 mAb
￿
PAF Receptor
PAF(10'7 M)
￿
Antagonist
Figure 7. An anti-GMP-140 mAb,
GI, inhibits GMP140 enhance-
ment of PAF-stimulated PMN ad-
hesiveness. Control buffer (HBSS/
A) or GMP140 (2 wg/ml) was in-
cubated with buffer or mAb GI,
S12, or T10 for 60 min at 4°C as
described (Moore et al., 1991).
The solutions were then warmed
to room temperature, PMNs were
added, and the suspensions incu-
bated for another 20 min at room
temperature. The PMNs were
then pelleted, resuspended in
HBSS/A, and added to EC. Buff-
er orPAFwas addedand adhesion
was determined after a 5-min in-
cubation. In parallel incubations,
PMN were pretreated with fibrin-
ogen (2 ug/ml) that had been
treated with buffer or the same
mAbas GMP140. Fibrinogen did
not enhance PMN adhesion in re-
sponse to PAF nor did any of the
mAbalterthe PAF-stimulated ad-
hesion of fibrinogen-pretreated
PMNs. Therefore the data are not
r
￿
shown to simplify the figure.it ligates a glycoprotein on thePMN surface by a lectinlike
interaction (Moore et al ., 1991) . The receptor appears to be
different from that for ELAM-1, since fluid-phase GMP-140
inhibits PMN adhesion to thrombin- or histamine-activated
EC but not to cytokine-activated EC under conditions in
which the adhesion is highly dependent on ELAM-1 . Be-
cause purified, immobilizedGMP-140 supports adhesion of
both fixed and native PMNs (Geng et al ., 1990) it is likely
that binding of GMP140 to its receptor on the PMN is a
bridging or capturing event that tethers thePMN to the EC .
This does not require activation of the CDll/CDI8 adhesive
mechanism (Fig. 3, right) . However, oneor more activation
responses of thePMN (Fig . 2), including functional upregu-
lation ofCDll/CD18 integrins (Fig. 3, left), is required for
maximal PMN adhesion to rapidly activated EC . This con-
trasts withalack ofrequirement for these events whenPMNs
bind to purified, immobilizedGMP-140 (Geng et al ., 1990),
or to EC that express GMP-140 for prolongedperiods (Patel
et al ., 1991) rather than transiently. Purified GMP-140 does
f
Unactivated PMN Figure 10. PMN adhesion to his-
tamine- or thrombin-activated
EC requires coordinate expres-
sion of GMP-140andPAR In his-
tamine- or thrombin-activated
ECGMP140 is rapidly expressed
GMP-140-&7T-W~CD11/C018
￿
on the EC surface where it binds
PAF--'~'`'_
￿
to a receptor on the neutrophil,
tethering it to theEC . This tether-
ing- .t does not require CDII/
CD18 heterodimers on the neutro-
phil . PAF is rapidly synthesized
and is coexpressed with GMP-140
on the EC. PAF ligates a receptor on the PMNs, serving as a signal for activation-dependent alteration in CDII/CD18 glycoproteins
(CDI la/CDl8 and CDllb/CD18) on the PMN plasma membrane that makes them competent to bind to counterreceptors on the EC . The
tethering component mediated by GMP-140 facilitates PAF interaction with its receptor on the PMN and enhances the PAF-stimulated
adhesiveness . Binding sites for activated CDII/CD18 heterodimers on the PAF-stimulated PMNs are present on both unactivated (not
shown) and activated EC . Antibodies to ICAM-1, anEC counterreceptor forCDlla/CD18andCDIlb/CD18, do not inhibit PAF-stimulated
PMN adhesion to EC (our unpublished observation) ; therefore the identity of the EC binding site(s) is unknown . See text for details .
Unactivated EC
Thrombin)
,,-CD11/CD18
Activation of PMN
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Figure 9 . Fluid phase GMP140
enhances FMLP or PMA-stimu-
lated PMN adhesion to EC .
PMNs were pretreated with buff-
er, GMP140(2 ttg/ml), orfibrino-
gen (2,ug/ml) as described in Fig .
6, pelleted, resuspended in fresh
buffer, and added to EC mono-
layers . PAF (10-' M), FMLP
(10-7 M), or phorbol myristate
acetate (PMA ; 10-7 M) wasadd-
ed andadhesion wasmeasured af-
ter5min . Thedata from three ex-
periments are shown .
not appear to directly activate thePMNadhesive mechanism
(Fig . 4), consistent with the finding that it does not induce
quantitative upregulation of CDll/CD18 integrins or shed-
ding of LAM-1 (Moore et al ., 1991) and does not directly
induce other activation responses of PMNs (Lorant et al .,
manuscript in preparation) . This indicates that a second pro-
adhesive molecule is involved in theEC-PMN interaction .
PAF that is rapidly synthesized and translocated to the
plasma membrane in histamine- or thrombin-activated EC
also ligates a receptor on thePMN and mediates juxtacrine
activation, a term originally used to describe activation of
target cells by membrane-anchored growth factors (Ankle-
saria et al ., 1990) . This interaction is blocked by specific
competitive receptor antagonists (Fig . 1 and Table I) or by
desensitizing the PAF receptor (Zimmerman et al ., 1985 ;
McIntyre et al ., 1986 ; Lewis et al ., 1988) . The neutrophil
PAF receptor is present on the unactivated PMNs (Hwang,
1988) and is linked to GTPase andcalcium regulatory signal
transduction mechanisms (Hwang, 1988 ; Prescott et al .,
CD 11 /CD 18 on activated
PMN amplifies binding,
facilitates polarization,
migration1990). A receptor for PAF was recently characterized by
molecular cloning from guinea pig lung (Honda et al., 1991).
Its structure predicts linkage to guanyl nucleotide-binding
regulatory proteins ("G-proteins"), consistent with these
characteristics and with our observation that PAF-stimulated
adhesiveness of PMNs requires an activation response by
metabolically competent cells. Activation of PMNs by PAF
orotherreceptor-mediated agonists results in increased quan-
titative or functional expression of several surface molecules
that may be involved in adhesion (Singer et al., 1989; Bohn-
sack, 1990; Stocks et al., 1990). However, PAF-stimulated
PMN binding to EC did not occur when anti-CD18 mAb
were present or when CDll/CD18-deficient PMNs were
studied. Therefore the component of adhesion signaled by
EC-associated PAF appears to exclusively require CDll/
CD18 glycoproteins and not other PMN adhesion molecules.
Both CDlla/CD18 and CDllb/CD18 mediate adhesion of
neutrophils stimulated by PAF (our unpublished observa-
tion). PAF-induced adhesion mediated by these integrins is
rapidly reversible (Zimmerman et al., 1985), consistent with
the transient adhesion of PMNs to thrombin- or histamine-
activated EC. The system of a signaling molecule that binds
to a receptor and recruits a separate adhesion effector on the
target cell is different from other examples ofjuxtacrine acti-
vation, where interaction of a cell-associated growth factor
with a receptor on the second cell mediates both adhesion
and activation (Anklesaria et al., 1990).
The fundamentally different mechanisms of adhesion pro-
vided by GMP-140 and PAF (tethering versus activation of
PMNs and recruitment of CDII/CD18 integrins) predicted
that their contributions to the adhesive interaction would be
additive. However, blocking either the PAF or GMP-140
component in parallel incubations in the same experiment
reduced adhesion by more than 50 % in each case (Fig. 1 and
Table I), indicating a cooperative mechanism ofadhesion. In
addition, in some experimentsblocking GMP-140 completely
inhibited adhesion, even though a significant PAF compo-
nent could be demonstrated (Fig. 1) . This suggests that the
tethering effect of GMP-140 is required for efficient interac-
tion of PAF in the EC plasma membrane with its receptor
on the PMN. The physical orientation ofPAF in the surface
membranes of activated EC is unknown, but it may be in the
outer leaflet of the lipid bilayer and thus relatively inacces-
siblebecause of surface proteins in adjacent areas (Zimmer-
man et al., 1990a) . Transient surface expression of GMP-
140 and tethering of PMNs by this mechanism may bring
local domains of the neutrophil plasma membrane into close
proximity with EC-associated PAF, facilitating receptor-
ligand interaction. In other systems, membrane-membrane
contact of cells mediated by one molecule is required to
initiate specific interactions between others (Rutishauser et
al ., 1988) .
In addition to physical considerations, binding of GMP-
140 in the EC plasma membrane to its receptor on neutro-
phils may potentiate the PAF-stimulated component of adhe-
sion . This is suggested by experiments in which PMNs were
treated with fluid phase GMP-140 and then stimulated with
exogenous PAF (Fig. 6-9) . The mechanismby which this oc-
curs is unknown, but the experiments in Fig. 9 suggest that
ligation of GMP-140 to its receptor on the PMN potentiates
CDl l/CD18 adhesive responses stimulated by other agonists
as well, and that protein kinase C-transduced events may be
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involved. Further definition of the mechanism will require
identification of the GMP-140 receptor (Moore et al., 1991 ;
Springer and Lasky, 1991) and characterization of the func-
tional changes in the PMN that result from ligation of the
receptor.
Our experiments indicating that fluid phase GMP-140 en-
hances PAF- or fMLP-stimulated PMN adhesion are at vari-
ance with observations that solubilized GMP-140 inhibits the
ability of certain agonists to induce the CD1 l/CD18 adhesive
mechanism (Gamble et al., 1990) and superoxide anion
generation (Wong et al., 1991). Gamble et al. (1990) sug-
gested that the putative soluble form of GMP-140 (Johnston
et al ., 1989a) may inhibit these responses as well . The nega-
tive effects might also be expected to be operative when
GMP-140 is expressed in membranes, since the soluble form
lacks only the membrane-spanning domain and does not
have deletions in the amino terminal lectin domain that inter-
acts with the PMN receptor (Johnston et al ., 1989a). GMP-
140 on the surface of activated EC might then inhibit CDl l/
CD18-dependent adhesiveness induced by EC-associated
PAR However, we found that antibodies to GMP-140 reduced
adhesion (Fig. 1 and Table I) rather than enhancing it. Taken
together, our experiments indicate that GMP-140in EC mem-
branes supports, rather than inhibits, CDII/CD18-depen-
dent adhesiveness. The experiments in Figs. 6-9 exclude the
possibility that the decrease in adhesion of PMNs treated
with fluid phase GMP-140 to rapidly activated EC (Fig. 5)
is due to inhibition of the CDl1/CD18-dependent component
of adhesion, and suggest that GMP-140 may potentiate the
CD1 l/CD18 adhesive mechanism. The reason for the differ-
ence between our results and those of Gamble et al. (1990)
is unknown.
If regulated coexpression of GMP-140 and PAF occurs in
response to EC agonists in vivo, the juxtacrine system that
we describe may confer additional biologic advantages be-
sides tightness of adhesion. First, the tethering effect of
GMP-140 provides specificity to the adhesive interaction
since receptors for GMP-140are present on PMNs and mono-
cytes but not platelets (Moore et al., 1991). In contrast, plate-
lets have PAF receptors and could potentially adhere to ac-
tivated endothelium in the absence of a requirement for
tethering by GMP-140. In other types of cell-cell interac-
tions, combinations of recognition molecules provide addi-
tional degrees of specificity over that of one molecular sys-
tem alone (Bixby et al., 1987; Rutishauser et al ., 1988) .
Second, the GMP-140 and CDll/CD8-dependent mecha-
nisms of adhesion may be variably operative under different
conditions of flow and stasis. The GMP-140-mediated,
CDll/ CD18-independent component may be required for
the PAF-stimulated, CD1I/CD18-dependent component to
operate in vessels subjected to high shear stress early in the
inflammatory response (Lawrence et al., 1990) . Third, the
transient coexpression of GMP-140 and PAF by EC may
influence subsequent events critical to the acute inflamma-
tory response. Adhesion of PMNs to endothelium, activa-
tion of the CDll/CD18 integrins, and polarization are re-
quired for effective migration of the leukocytes to
extravascular sites (Movat, 1985 ; Anderson and Springer,
1987; Smith et al., 1989; Kishimoto et al ., 1990; Springer,
1990) . The signaling component provided by EC-associated
PAF may facilitate this sequence of events. Coexpression of
tethering and signaling molecules by activated endothelium
232provides a mechanism for both adhesion and regulated func-
tional alteration of the leukocyte at the first committed step
in the acute inflammatory response. This paradigm, which
we have defined in rapidly activated EC, may be generally
applicable to other leukocyte-endothelial cell interactions.
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Note Added in Proof. Recently it was reported that GMP-140 and CD 11/
CDI8 integrins act cooperatively to enhance the avidity of PMN adhesion
in a model membrane system (Lawrence, M. B., and T. A. Springer. 1991.
Leukocytes roll on a selectin at physiologic flow rates: distinction from and
prerequisite for adhesion through integrins. Cell, 65:1-20), similar to the
juxtacrine system in endothelium described here. That study also supports
the observation that GMP-140 neither directly induces nor inhibits CD I I/
CD18-mediated adhesiveness of PMNs.
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